Stroke News and Research

RSS

A stroke is a medical emergency. Strokes happen when blood flow to your brain stops. Within minutes, brain cells begin to die. There are two kinds of stroke. The more common kind, called ischemic stroke, is caused by a blood clot that blocks or plugs a blood vessel in the brain. The other kind, called hemorrhagic stroke, is caused by a blood vessel that breaks and bleeds into the brain. "Mini-strokes" or transient ischemic attacks (TIAs), occur when the blood supply to the brain is briefly interrupted.

Health inequalities still exist between England's richest and poorest

Significant health inequalities still exist between the country's richest and poorest according to the latest findings from the biggest annual survey of health in England, The Health Survey for England. The survey, conducted by the National Centre for Social Research and UCL and funded by The NHS Information Centre, shows that people in the lowest income households continue to experience much worse outcomes across key health measures than people in the highest income households.

17 Dec 2010

Study highlights death or rehospitalization rates for Medicare beneficiaries with ischemic stroke

Nearly two-thirds of Medicare beneficiaries discharged from hospitals after ischemic stroke die or are readmitted within one year, researchers report in Stroke: Journal of the American Heart Association.

17 Dec 2010

Ischemic stroke patients at substantial risk once leaving the hospital: Study

A UCLA-led has study found that after leaving the hospital, nearly two-thirds of Medicare beneficiaries hospitalized for acute ischemic stroke either died or were rehospitalized within a year.

17 Dec 2010

City Tech Nursing Professor provides community-based care plan to study difference in health outcomes

Patients with diabetes who follow a self-care regimen generally have success in controlling their disease. But what about patients whose other health conditions, such as cognitive impairment and/or depression, create barriers to effective treatment?

17 Dec 2010

AHA recognizes UC Irvine Medical Center's commitment to high-quality cardiac care

The American Heart Association has recognized UC Irvine Healthcare's commitment to the highest standards of care for heart failure patients.

17 Dec 2010

Genentech confirms EMA, FDA updates on Avastin for metastatic breast cancer

Genentech, a member of the Roche Group, confirmed that following the reviews of Avastin® (bevacizumab) in metastatic breast cancer by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), the following regulatory announcements were made by the individual health authorities:

17 Dec 2010

Bayer's SAFYRAL oral contraceptive receives FDA approval

Bayer HealthCare Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved a new oral contraceptive (OC), SAFYRAL™ (drospirenone 3 mg/ ethinyl estradiol 30 mcg/ levomefolate calcium 451 mcg tablets and levomefolate calcium 451 mcg tablets). In women who choose an OC for birth control, SAFYRAL raises folate levels for the purpose of reducing the risk of rare neural tube defects (NTDs) in a pregnancy conceived while taking SAFYRAL or shortly after discontinuing it.

17 Dec 2010

FDA approves Neuralstem's IND to initiate NSI-189 Phase Ia safety trial in major depression

Neuralstem, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to initiate a Phase Ia safety trial to test NSI-189, its first small molecule compound, in major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression and other diseases, such as Alzheimer's disease.

17 Dec 2010

FDA recommends removal of breast cancer indication from Avastin label

The U.S. Food and Drug Administration announced today that the agency is recommending removing the breast cancer indication from the label for Avastin (bevacizumab) because the drug has not been shown to be safe and effective for that use.

17 Dec 2010

Manhattan Pharmaceuticals reports preliminary results from AST-915 Phase 1/2 study in essential tremor

Manhattan Pharmaceuticals, Inc. announced preliminary results today from a Phase 1/2 study of AST-915 for the treatment of essential tremor. Data from this single dose study demonstrated that AST-915 was safe and well tolerated and demonstrated a clear effect on tremor power.

16 Dec 2010

Second brain death exam impacts organ donation rates

Requiring a second exam on a person who is considered brain dead may be unnecessary, according to a study on the impact of a second brain death exam on organ donation rates. The research is published in the December 15, 2010, online issue of Neurology®, the medical journal of the American Academy of Neurology.

16 Dec 2010

DeCODE Genetics identify SNPs to derive PSA threshold for diagnosing prostrate cancer

Scientists from deCODE genetics and academic colleagues from Iceland, the UK, US, Netherlands, Spain and Romania today report the discovery of a set of single-letter variations in the sequence of the human genome that impact individual baseline levels of prostate specific antigen, or PSA.

16 Dec 2010

SBUMC to unveil one-of-a-kind neuroendovascular simulator

Stony Brook University Medical Center will unveil this Friday a one-of-a-kind neuroendovascular simulator that recreates vasculature in the brain, including scenarios of damaged vessels from acute stroke, brain aneurysms, and other cerebrovascular anomalies. Affectionately known in the lab as "Headley".

16 Dec 2010

Use of vitamin K antagonists is driven by availability of oral formulation

Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that, in the treatment of atrial fibrillation, surveyed European cardiologists indicate that use of vitamin K antagonists, as a class, is primarily driven by the availability of an oral formulation, overall low cost and widespread inclusion on European medical society guidelines and hospital formularies.

16 Dec 2010

Synthetic derivative of curry spice can be effective neuroprotective for stroke and TBI

A synthetic derivative of the curry spice turmeric, made by scientists at the Salk Institute for Biological Studies, dramatically improves the behavioral and molecular deficits seen in animal models of ischemic stroke and traumatic brain injury.

16 Dec 2010

Researchers examine expression of toxic mRNA in patients with Fragile X Tremor Ataxia Syndrome

Expression of a toxic RNA that leads to Fragile X Tremor Ataxia Syndrome is modifiable by genetic or pharmacologic means, according to new research from U-M Medical School scientists.

15 Dec 2010

China Nuokang receives SFDA manufacturing license for Dipyridamole Aspirin

China Nuokang Bio-Pharmaceutical Inc., a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hospital-based medical products, today announced that the Company has received the manufacturing license from the State Food and Drug Administration ("SFDA") for Dipyridamole Aspirin, a stroke-prevention product developed in-house.

15 Dec 2010

Study: HUCBs boost survival and maturation of hippocampal neurons

Laboratory culture studies examining the activity of human umbilical cord blood cells on experimental models of central nervous system aging, injury and disease, have shown that HUCBs provide a 'trophic effect' that enhances survival and maturation of hippocampal neurons harvested from both young and old laboratory animals.

15 Dec 2010

Health report card for NSW

The latest report on NSW health shows that it is better than most in heart disease and cancer statistics. However 60% of the state are overweight or obese says the report and 70% of the NSW adults say they have been diagnosed with long-term illnesses.

14 Dec 2010

Preliminary results from Phase 1b/2a trial of MediciNova's ibudilast in opioid addicts announced

Drug addiction investigators with joint appointments at Columbia University Medical Center and the New York State Psychiatric Institute along with MediciNova Inc, a biopharmaceutical company publicly traded on the Nasdaq Global Market and the Jasdaq Market of the Osaka Securities Exchange, today reported preliminary results of the company's neurological drug candidate, ibudilast (MN-166/AV411), in a Phase 1b/2a trial in opioid addicts. The study was largely funded by the National Institute on Drug Abuse (NIDA) with MediciNova supplementation.

14 Dec 2010

Stroke News and Research

Further Reading

Health inequalities still exist between England's richest and poorest

Study highlights death or rehospitalization rates for Medicare beneficiaries with ischemic stroke

Ischemic stroke patients at substantial risk once leaving the hospital: Study

City Tech Nursing Professor provides community-based care plan to study difference in health outcomes

AHA recognizes UC Irvine Medical Center's commitment to high-quality cardiac care

Genentech confirms EMA, FDA updates on Avastin for metastatic breast cancer

Bayer's SAFYRAL oral contraceptive receives FDA approval

FDA approves Neuralstem's IND to initiate NSI-189 Phase Ia safety trial in major depression

FDA recommends removal of breast cancer indication from Avastin label

Manhattan Pharmaceuticals reports preliminary results from AST-915 Phase 1/2 study in essential tremor

Second brain death exam impacts organ donation rates

DeCODE Genetics identify SNPs to derive PSA threshold for diagnosing prostrate cancer

SBUMC to unveil one-of-a-kind neuroendovascular simulator

Use of vitamin K antagonists is driven by availability of oral formulation

Synthetic derivative of curry spice can be effective neuroprotective for stroke and TBI

Researchers examine expression of toxic mRNA in patients with Fragile X Tremor Ataxia Syndrome

China Nuokang receives SFDA manufacturing license for Dipyridamole Aspirin

Study: HUCBs boost survival and maturation of hippocampal neurons

Health report card for NSW

Preliminary results from Phase 1b/2a trial of MediciNova's ibudilast in opioid addicts announced

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News